PL2654785T3 - Wzmocniona odpowiedź immunologiczna u gatunków wołowatych - Google Patents

Wzmocniona odpowiedź immunologiczna u gatunków wołowatych

Info

Publication number
PL2654785T3
PL2654785T3 PL11804675T PL11804675T PL2654785T3 PL 2654785 T3 PL2654785 T3 PL 2654785T3 PL 11804675 T PL11804675 T PL 11804675T PL 11804675 T PL11804675 T PL 11804675T PL 2654785 T3 PL2654785 T3 PL 2654785T3
Authority
PL
Poland
Prior art keywords
immune response
enhanced immune
bovine species
bovine
species
Prior art date
Application number
PL11804675T
Other languages
English (en)
Inventor
Albert Abraham
Daniel Keil
Jason NICKELL
Christian Weiss
Original Assignee
Bayer Intellectual Property Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property Gmbh filed Critical Bayer Intellectual Property Gmbh
Publication of PL2654785T3 publication Critical patent/PL2654785T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11804675T 2010-12-22 2011-12-20 Wzmocniona odpowiedź immunologiczna u gatunków wołowatych PL2654785T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426255P 2010-12-22 2010-12-22
EP11804675.4A EP2654785B1 (en) 2010-12-22 2011-12-20 Enhanced immune response in bovine species
PCT/EP2011/073414 WO2012084951A1 (en) 2010-12-22 2011-12-20 Enhanced immune response in bovine species

Publications (1)

Publication Number Publication Date
PL2654785T3 true PL2654785T3 (pl) 2019-09-30

Family

ID=45444595

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11804675T PL2654785T3 (pl) 2010-12-22 2011-12-20 Wzmocniona odpowiedź immunologiczna u gatunków wołowatych

Country Status (35)

Country Link
US (3) US20130295167A1 (pl)
EP (1) EP2654785B1 (pl)
JP (2) JP6058550B2 (pl)
KR (1) KR101940826B1 (pl)
CN (2) CN108379576A (pl)
AR (1) AR084510A1 (pl)
AU (1) AU2011347464B2 (pl)
BR (1) BR112013016231B1 (pl)
CA (1) CA2822359C (pl)
CL (1) CL2013001833A1 (pl)
CO (1) CO6761354A2 (pl)
CR (1) CR20130312A (pl)
DK (1) DK2654785T3 (pl)
DO (1) DOP2013000149A (pl)
EC (1) ECSP13012709A (pl)
ES (1) ES2722204T3 (pl)
GT (1) GT201300168A (pl)
HK (1) HK1259341A1 (pl)
HR (1) HRP20190779T1 (pl)
HU (1) HUE043473T4 (pl)
IL (1) IL226733B (pl)
LT (1) LT2654785T (pl)
MX (1) MX345854B (pl)
MY (1) MY167159A (pl)
NZ (1) NZ612285A (pl)
PH (1) PH12013501348B1 (pl)
PL (1) PL2654785T3 (pl)
PT (1) PT2654785T (pl)
RU (1) RU2606855C2 (pl)
SI (1) SI2654785T1 (pl)
TR (1) TR201906323T4 (pl)
TW (1) TWI587877B (pl)
UA (1) UA118537C2 (pl)
UY (1) UY33821A (pl)
WO (1) WO2012084951A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2654785T3 (da) * 2010-12-22 2019-06-24 Bayer Ip Gmbh Forøget immunrespons hos kvægracer
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP3110940A1 (en) 2014-02-28 2017-01-04 Bayer Animal Health GmbH Immunostimulatory plasmids
CN104825393B (zh) * 2015-01-16 2017-11-10 艾美科健(中国)生物医药有限公司 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法
US20190233825A1 (en) * 2015-06-26 2019-08-01 Bayer Animal Health Gmbh Methods of modulating cytosolic dna surveillance molecules
CN108712912B (zh) * 2015-07-31 2022-05-10 拜耳动物保健有限责任公司 在水生物种中增强的免疫应答
TW201718001A (zh) * 2015-07-31 2017-06-01 拜耳動物保健有限公司 豬物種中增強之免疫反應
EP3490598A1 (en) * 2016-07-26 2019-06-05 Bayer Animal Health GmbH Increased fertility in bovine species
KR102069680B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
CN111801419A (zh) * 2017-12-15 2020-10-20 拜耳动物保健有限责任公司 免疫刺激性寡核苷酸
CN108812546A (zh) * 2018-09-07 2018-11-16 四川省草原科学研究院 适于青藏高原地区牦牛运输减少应激的药物及使用方法
CN109646435B (zh) * 2019-01-11 2021-08-03 山东省农业科学院奶牛研究中心 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用
WO2020194735A1 (ja) 2019-03-28 2020-10-01 日本電気株式会社 情報処理装置、サーバ割当装置、方法、及びコンピュータ可読媒体
CN114480663A (zh) * 2021-11-15 2022-05-13 贵州省畜牧兽医研究所 用于检测猪源差异脲原体的引物对、试剂盒及检测方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5427791A (en) 1992-08-05 1995-06-27 Regents Of The University Of Minnesota Embryonal vaccine against Newcastle disease
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
EP1955709B1 (en) 1999-03-26 2012-03-14 Vical Incorporated Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
RU2158587C1 (ru) * 1999-05-11 2000-11-10 Ставропольское научно-производственное объединение "Пульс" Антибактериальное средство для лечения заболеваний сельскохозяйственных животных и птиц, способ профилактики и лечения цыплят при заболеваниях бактериальной этиологии, способ лечения респираторной болезни телят бактериальной этиологии, способ профилактики туберкулеза у крупного рогатого скота
US20040002472A1 (en) * 2000-01-21 2004-01-01 Audonnet Jean-Christophe Francis Vaccination or immunization using a prime-boost regimen
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
JP4261195B2 (ja) 2001-04-24 2009-04-30 イノジェネティックス・ナムローゼ・フェンノートシャップ 酵母のコア−グリコシル化されたhcvエンベロープタンパク質の発現
WO2003004051A2 (en) * 2001-07-02 2003-01-16 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
NZ542652A (en) * 2003-03-26 2008-04-30 Wyeth Corp Immunogenic composition and methods
PE20050386A1 (es) * 2003-05-29 2005-06-23 Schering Plough Ltd Composiciones farmaceuticas de florfenicol
JP2007509040A (ja) * 2003-10-11 2007-04-12 イネックス ファーマシューティカルズ コーポレイション 先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物
UY29915A1 (es) 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
JP2008094763A (ja) * 2006-10-12 2008-04-24 Takeshi Ogura 海洋ミネラル成分からなるインターフェロンγ産生増強剤
US20110111017A1 (en) * 2008-02-24 2011-05-12 Government Of The United States Of America,As Rep. By The Secretary,Dept. Of Health And Human Servic Use of immunogenic compositions for the treatment or prevention of pathogen infections
CA2719614C (en) * 2008-03-25 2018-05-01 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
EP2362780B1 (en) * 2008-10-31 2019-12-25 Boehringer Ingelheim Animal Health USA Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
SI2992899T1 (sl) 2009-05-14 2020-10-30 Bayer Intellectual Property Gmbh Povečan imunski odziv pri ptičjih vrstah
DK2654785T3 (da) * 2010-12-22 2019-06-24 Bayer Ip Gmbh Forøget immunrespons hos kvægracer

Also Published As

Publication number Publication date
CN108379576A (zh) 2018-08-10
PH12013501348B1 (en) 2019-11-22
HRP20190779T1 (hr) 2019-06-28
HUE043473T4 (hu) 2019-12-30
CA2822359A1 (en) 2012-06-28
UA118537C2 (uk) 2019-02-11
CN103501810A (zh) 2014-01-08
CO6761354A2 (es) 2013-09-30
NZ612285A (en) 2015-09-25
ES2722204T3 (es) 2019-08-08
DK2654785T3 (da) 2019-06-24
MX345854B (es) 2017-02-17
DOP2013000149A (es) 2013-08-15
KR101940826B1 (ko) 2019-01-21
WO2012084951A1 (en) 2012-06-28
GT201300168A (es) 2015-02-23
ECSP13012709A (es) 2013-08-30
US20130295167A1 (en) 2013-11-07
MX2013007064A (es) 2013-08-21
TWI587877B (zh) 2017-06-21
JP2017036290A (ja) 2017-02-16
SI2654785T1 (sl) 2019-06-28
RU2013133730A (ru) 2015-01-27
AU2011347464B2 (en) 2016-08-25
HUE043473T2 (hu) 2019-08-28
MY167159A (en) 2018-08-13
CL2013001833A1 (es) 2014-06-20
TW201306877A (zh) 2013-02-16
KR20130132926A (ko) 2013-12-05
JP6058550B2 (ja) 2017-01-11
BR112013016231B1 (pt) 2021-03-23
IL226733B (en) 2020-06-30
RU2606855C2 (ru) 2017-01-10
AU2011347464A1 (en) 2013-07-11
AR084510A1 (es) 2013-05-22
PT2654785T (pt) 2019-06-25
JP2014500292A (ja) 2014-01-09
CA2822359C (en) 2021-06-01
US10751361B2 (en) 2020-08-25
CR20130312A (es) 2013-10-17
PH12013501348A1 (en) 2013-08-28
BR112013016231A2 (pt) 2016-09-27
AU2011347464A2 (en) 2013-08-22
US20190201434A1 (en) 2019-07-04
EP2654785B1 (en) 2019-03-20
EP2654785A1 (en) 2013-10-30
HK1259341A1 (zh) 2019-11-29
US20140010865A1 (en) 2014-01-09
LT2654785T (lt) 2019-07-10
TR201906323T4 (tr) 2019-05-21
UY33821A (es) 2012-07-31

Similar Documents

Publication Publication Date Title
PH12013501348A1 (en) Enhanced immune response in bovine species
ZA201307919B (en) Composition and method for enhancing an immune response
GB2481482B (en) Improvements in sensors
IL230511A0 (en) 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
PT2665818T (pt) Expressão de proteínas em plantas
IL215900A0 (en) Enhanced immune response in avian species
PT2594282E (pt) Lactoferrina e a matéria branca
GB2490393B (en) Improvements in sensors
EP2521787A4 (en) IMPROVED PROTEIN EXPRESSION
GB201321941D0 (en) Title in Foreign
GB201001966D0 (en) All in one pot stop
GB201014323D0 (en) Improvements in semiconductor processing
GB201016990D0 (en) Improvements in swimfeeder devices
GB201001384D0 (en) Light-fitting and associated methods
GB201100062D0 (en) Improvements in ventilation
LT3689878T (lt) 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk inhibitoriai
GB201000696D0 (en) Improvements in or relating to casks